CG Oncology, Inc. (CGON)
NASDAQ: CGON · IEX Real-Time Price · USD
30.97
+2.96 (10.57%)
At close: May 16, 2024, 4:00 PM
31.00
+0.03 (0.10%)
Pre-market: May 17, 2024, 4:00 AM EDT
CG Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CG Oncology stock have an average target of 63.75, with a low estimate of 50 and a high estimate of 75. The average target predicts an increase of 105.84% from the current stock price of 30.97.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 |
| Buy | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $43 → $50 | Hold → Strong Buy | Upgrades | $43 → $50 | +61.45% | May 14, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $50 | Hold → Strong Buy | Upgrades | $50 | +61.45% | May 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +142.17% | May 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $75 | Buy | Reiterates | $75 | +142.17% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +142.17% | May 6, 2024 |
Financial Forecast
Revenue This Year
1.02M
from 204.00K
Increased by 400.00%
Revenue Next Year
11.05M
from 1.02M
Increased by 983.33%
EPS This Year
-1.47
from -15.65
EPS Next Year
-1.73
from -1.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.2M | 34.1M | 130.1M | 238.4M | 435.8M |
| Avg | 1.0M | 11.1M | 64.6M | 156.9M | 360.4M |
| Low | n/a | n/a | 26.7M | 79.1M | 285.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,444.1% | 3,245.6% | 1,076.9% | 268.8% | 177.7% |
| Avg | 400.0% | 983.3% | 484.8% | 142.8% | 129.6% |
| Low | - | - | 141.3% | 22.4% | 82.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.76 | -1.17 | -1.28 |
| Avg | -1.47 | -1.73 | -1.35 |
| Low | -1.96 | -2.32 | -1.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.